AstraZeneca invests USD 2.00 billion and AstraZeneca stock costs EUR 141.25

{
  "signal_id": "765cb0c7-68c9-b8c3-b034-b83d18a2c4be",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-10-02T11:41:30+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/astrazeneca-invests-usd-2-00-billion-and-astrazeneca-stock-costs-eur-141-25/70215239",
    "title": "AstraZeneca invests USD 2.00 billion and AstraZeneca stock costs EUR 141.25 - ad-hoc-news.de",
    "excerpt": "AstraZeneca invested USD 2.00 billion in Summit Therapeutics on September 29, 2026, securing access to the cancer drug ivonescimab. AstraZeneca stock was trading at EUR 141.25 at Lang & Schwarz on October 2, 2026, up 0.61 percent versus the prior close of EUR 140.40. As IG reported on September 29, 2026, the investment gives AstraZeneca rights equivalent to 12.00 percent of Summit's outstanding common stock, or 10.60 percent on a fully diluted basis. The companies also plan clinical trials combining ivonescimab with AstraZeneca's antibody-drug conjugate sonesitatug vedotin. The structure limits the immediate commitment to a strategic investment rather than a full acquisition. The next external milestone is a November 14, 2026, FDA decision for ivonescimab in a lung-cancer setting, according to the same IG report. AstraZeneca generated USD 30.70 billion of revenue in the first half of 2026, up 6.00 percent year over year, while core operating profit increased 11.00 percent, according to IG . Oncology accounted for 46.00 percent of first-half revenue and produced USD 14.10 billion of sales, up 15.00 percent at constant exchange rates. In its first-half 2026 earnings call, SquawkNews reported that core earnings per share grew 11.00 percent. Management reiterated full-year guidance for total revenue growth in the mid- to high-single-digit percentage range and core earnings per...",
    "summary": "AstraZeneca's core earnings per share grew 11% in the first half of 2026.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2705378_1920_1080.webp",
    "confidence": 0.9,
    "published_at": "2026-10-02T11:41:30Z",
    "article_sentence": "In its first-half 2026 earnings call, SquawkNews reported that core earnings per share grew 11.00 percent."
  }
}

curl https://signals.autobound.ai/v1/signals/765cb0c7-68c9-b8c3-b034-b83d18a2c4be \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"astrazeneca.com","limit":20}'